Hamburger

Call: 1-202-476-5000

 
For Healthcare Professionals
Physician Portal
Refer a Patient
About Our Physicians
Medical Staff On-Boarding
Graduate Medical Education
Continuing Medical Education
Board Review Home Study
Children's Grand Rounds
Archived Grand Rounds
Board Review Course
Medical Student Education
Nursing at Children's
Publications
Children's National Health Network
Children's IQ Network
Helpful Resources
Children's Alumni Association
CTI: Web-based Training
 
 
Email 

this page Email This Page
Print this page Print This Page
 

  Join Us On:
  Follow Children's on Facebook  Facebook
  Follow Children's on Twitter  Twitter
  Watch Children's on YouTube  YouTube
 
 
     
 

8th International Conference on Pediatric Renal Tumor Biology
Presented by The Pablove Foundation and Children’s National Medical Center

 Children's National Medical Center            
Pablove Foundation



Date: May 8-10, 2013
Location: Hyatt Regency Hotel in Bethesda, Md.
1 Bethesda Metro Center, Bethesda, MD 20814
A room block is available for conference attendees at a discounted rate of $179/night for single occupancy.
Book now!

Fees and Registration Information
• Full Meeting (includes attendance to meeting, CME credits, breakfast each day, two lunches, tour of Washington DC and dinner on May 8, and reception at Children’s National Medical Center on May 9): $350
• Guest Registration (includes tour of Washington DC, dinner and reception at Children’s National Medical Center): $150
• No Refunds
• No Group Discounts
• Family Day: Free to patient families and survivors, courtesy of the Pablove Foundation

Programmatic Topics
• Renal Development and WT1 Biology
• “Omics” of Pediatric Renal Tumors
• Clinical and Biological Prognostic Markers
• Molecular Targets and New Drug Development
• Non-Wilms Renal Tumors
• Family Day: Targeted presentations for patient families and survivors (May 10)
8th International Conference on Pediatric Renal Tumor Biology
  Download the Family day flier
Download the Family Day flier (courtesy of the Pablove Foundation)


Schedule: Day 1 | Day 2 | Day 3
Wednesday, May 8, 2013
7:30- 8:30 am
Registration/ Continental Breakfast
8:30 am
Welcome and Introduction
Jeffrey Dome, MD, PhD, Children’s National
8:30 am- 1:00 pm
Session 1: Renal Development and Wilms Tumor Biology
Moderators: Vicki Huff, PhD, and Kathy Pritchard-Jones, MD, PhD
8:30-9:30 am Keynote Lecture: Wt1 and mesenchyme regulation in Wilms tumor, development and tissue homeostasis
Nicholas Hastie, CBE, FRS, FRSE, Director, MRC Human Genetics Unit and Director
Institute of Genetics and Molecular Medicine, University of Edinburgh


Abstract Presentations
9:30-9:45 am
Charlton J et al.: Methylation profiling to characterize the progression of nephrogenic rests to Wilms tumor
9:45-10:00 am Holmquist-Mengelbier L et al.: IRX3 in Wilms tumor differentiation and progression – a future prognostic and therapeutic target?
10:00-10:30 am Coffee Break
10:30-11:15 am Invited Lecture: Human renal developmental progenitors link kidney regeneration and tumorigenesis.  Benjamin Dekel, MD, PhD

Abstract Presentations
11:15 – 11:30 am Lovvorn B et al.: CITED1 confers stemness top Wilms tumor and enhances tumorigenic responses when enriched in the nucleus
11:30-11:45 am Sehic D et al.: An evaluation of SIX1 CITED1 and CD56 protein expression for selective identification of blastemal elements in Wilms tumor
11:45 am-12:00 pm Valind A et al.: Somatic genome evolution and aneuploidy tolerance in Wilms tumor
12:00 -12:15 pm Gisselsson D: Mechanisms regulating the generation, elimination and spatial distribution of genomic imbalances in Wilms tumor
12:15-12:30 pm Apps JR et al.: Characterization of intra-tumoral genetic heterogeneity in Wilms tumors
12:30-12:45 pm Questions/ Discussion
12:45-1:45 pm Lunch
1:45-2:45 pm
Session 2: Novel Clinical and Biological Prognostic Factors
Moderators: Paul Grundy, MD, and Manfred Gessler, PhD
1:45-2:15 pm
Update on Risk Stratification-SIOP
Kathy Pritchard-Jones, MD, PhD
2:15-2:45 pm
Update on Risk Stratification-COG
Elizabeth Mullen, MD

Abstract Presentations
2:45-3:00 pm Gratias E et al.: Gain of 1q is associated with inferior event-free survival in all
stages of favorable histology Wilms tumor: A report from the Children’s Oncology Group
3:00 – 3:15 pm Review of 1q, 1p, 16q Biomarker Posters: Kathy Pritchard-Jones, MD, PhD
- Vokuhl, C: 1q gain in Wilms tumors treated in the SIOP2001/GPOH trial
- Pritchard-Jones K et al.: Copy number analysis of 1q gain in Wilms tumor by multiplex
ligation-dependent probe amplification
- Dainese L et al.: 1p and 16q allelic loss in Wilms tumors (Nephroblastoma) in the
SFCE/SIOP 2001 Nephroblastoma trial – Are they correlated with pathology
3:15-3:45 pm Questions/Discussion of 1q gain, 1p/16q LOH
3:45-4:00 pm
Coffee Break

Abstract Presentations
4:00-4:15 pm Gadd S et al.: Evidence supporting the retention of the p53 pathway in a subset
of anaplastic Wilms tumors.
4:15-4:30 pm Maschietto M et al.: TP53 mutation status defines two distinct classes of diffuse
anaplastic Wilms tumors
4:30-5:00 pm Discussion of p53 in Anaplastic Wilms Tumor- David Gisselsson
5:30 pm
Tour of Washington, DC
Dinner
Carmine’s Restaurant, Washington, DC
(Buses depart from Hyatt Regency at 5:30pm)



Thursday, May 9, 2013
7:30- 8:30 am
Registration/ Continental Breakfast
8:30 am-1:00 pm Session 3: Genomics and Proteomics of Pediatric Renal Tumors
Moderators: Elizabeth Perlman, MD, and Richard Williams, PhD
8:30-9:30 am Keynote Lecture: Targeting Chromosomal Translocation Fusion Proteins with Small Molecules
Jeffrey Toretsky, MD, Georgetown Lombardi Cancer Center

Abstract Presentations
9:30-9:45 am Perotti D et al.: From primary Wilms tumor to recurrent Wilms tumor: what
happens
9:45-10:00 am Guertl-Lackner B et al: Deregulation of miRNAs targeting ACVR2B in
nephroblastomas
10:00-10:15 am Ludwig N et al.: Specific miRNA and autoantibody signatures in blood of Wilms tumor patients
10:15-10:45 am Coffee Break/ Poster Viewing

Abstract Presentations
10:45-11:00 am Nourkami-Tutdibi et al.: Protein signatures and immune response pattern in childhood renal tumors
11:00-11:15 am Kentsis A et al.: Urine proteomics of renal tumors for discovery of new prognostic markers and therapeutic targets
11:15-11:30 am Graf N et al.: The need for virtual biobanks in international clinical trials – A solution for SIOP-RTSG within the p-medicine project
11:30 am-12:00 noon Questions/ Discussion
12:00-1:00 pm
Lunch

Session 4: Non-Wilms Renal Tumors
Moderators: Marry Van den Heuvel-Eibrink, MD, PhD, and James Geller, MD
1:00-2:00 pm
Keynote Lecture: Current and future treatment options for adult RCC: Lessons Learned
Michael Atkins, MD, Deputy Director, Georgetown Lombardi Cancer Center

Abstract Presentations
2:00-2:15 pm Cajaiba MM et al.: Characterization of pediatric renal cell carcinomas registered on AREN03B2
2:15- 2:30 pm Karlsson J et al.: Clear cell sarcoma of the kidney mimics cells of the intermediate mesoderm: indications of an early embryonic origin
2:30-2:45 pm Bissler, J et al: Pericyte Origin for Tuberous Sclerosis-Associated Renal Angiomyolipoma and Implications for Therapy
2:45-3:15 pm Questions/ Discussion
3:15-3:45 pm
Coffee Break
3:45-4:45 pm
Keynote Lecture: DICER1 mutations and risk for tumors of the kidney. Ashley Hill, MD
4:45-5:05 pm Discussion of DICER1 posters- Ashley Hill, MD
Cajaiba MM et al.: Revisiting the morphological spectrum of pediatric cystic nephromas: the COG experience
Doros, L et al.: Somatic DICER1 mutations in sporadic cases of cystic nephroma
Wu MK et al.: Biallelic DICER1 mutations occur in Wilms tumors
5:05-5:30 pm Discussion
6:30-8:30 pm
Reception
Children’s National Medical Center
(Buses to depart from Hyatt Regency at 6:00 pm)


Friday, May 10, 2013
**Family Day sponsored by the Pablove Foundation
7:30-8:30 am
Registration/ Continental Breakfast
8:30-10:30 am Session 5: Novel Agents/Therapeutic Targets for Pediatric Renal Tumors
Moderators: James Geller, MD, and Filippo Spreafico, MD
8:30-9:30 am Keynote Lecture: Preclinical testing for renal tumors – Lessons from the Pediatric Preclinical Testing Program (PPTP)
Malcolm Smith, MD, PhD, Associate Branch Chief, Pediatric Oncology, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute

Abstract Presentations
9:30-9:50 am Wegert J et al.: Primary cell cultures as an in vitro Wilms tumor model
9:50-10:05 am Urbach A,  Implicating the pluripotency factor Lin28 in kidney development and Wilms Tumor
10:05-10:20 am James Geller, MD: Recent phase 1 and 2 clinical trials for Wilms tumor: James Geller, MD
10:20-10:40 am Questions/ Discussion: How to bring forward new drugs for pediatric renal tumors?
10:40-11:00 am Coffee Break/ Poster Viewing

Session 6: Non-Wilms Renal Tumors- Part 2
Moderators: Conrad Fernandez, MD, and Eric Gratias, MD
11:00 am-12:00 Noon
Keynote Lecture: The Genetic Basis of Kidney Cancer: A Metabolic Disease
Marston Linehan, MD, Chief, Urologic Oncology Branch, National Cancer Institute

Abstract Presentations
12:00-12:20 pm Bissler et al.: Treatment of Angiomyolipoma, locoregional control and results of the EXIST-2 trial.
12:20-12:35 pm Reisman D et al.: Loss of BRG1 and BRM in pediatric rhabdoid tumors
12:35-12:50 PM: Hu Y et al.: Effect of telomerase inhibition on the growth of malignant rhabdoid tumor in vitro and in vivo
12:50-1:00 pm Discussion
1:00-2:30 pm
Lunch (on own)
2:30-5:30 pm
Session 7: Updates for Patients and Families
Moderators: Jeffrey Dome, MD, PhD, and Norbert Graf, MD
Expert Panel: Kathy Pritchard-Jones, MBBS, Elizabeth Mullen, MD, Elizabeth Perlman, MD, James Geller, MD, Conrad Fernandez, MD
2:30-3:00 pm
New Developments in Renal Tumor Treatment and Biology-The Children’s Oncology Group Perspective
Jeffrey Dome, MD, PhD, Chair, Children’s Oncology Group Renal Tumor Committee
3:00-3:30 pm
New Developments in Renal Tumor Treatment and Biology-The International Society of Pediatric Oncology Perspective
Norbert Graf, MD, Chair, International Society of Pediatric Oncology Renal Tumour Study Group
3:30-5:30 pm
Questions from families to Expert Panel
Expert Panel:
• Jeffrey Dome, MD, PhD (United States)
• Norbert Graf, MD (Germany)
• Kathy Pritchard-Jones, MD, PhD (United Kingdom)
• Elizabeth Mullen, MD (United States)
• Elizabeth Perlman, MD (United States)
• James Geller, MD (United States)
• Conrad Fernandez, MD (Canada)






CME Information

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The George Washington University School of Medicine and Health Sciences and Children’s National Medical Center. The George Washington University School of Medicine and Health Sciences is accredited by the ACCME to provide continuing medical education for physicians

Physician CME Credit
The George Washington University School of Medicine and Health Sciences designates this live activity for a maximum of 24 AMA Physician Recognition Award Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evaluation and Claiming Credit/ Attendance
At the close of the event, participants will be e-mailed a link to the evaluation. Upon completing the evaluation, participants will be able to complete a credit claim form and print/save a certificate of completion or attendance.

Learning Objectives
1. To recognize new developments in the biology of Wilms tumor, pediatric renal cell carcinoma, and malignant rhabdoid tumor
2. To recognize genetic predisposition syndromes that are associated with pediatric renal tumors
3. To identify novel prognostic biomarkers for Wilms tumor
4. To recognize novel molecular targets for pediatric renal tumors, potential drugs for those targets, and clinical trials available to patients.
5. To discuss the concerns of patients and families affected by pediatric renal tumors to try to improve family-centered care.

Disclosures
GW relies upon its faculty to provide information in a manner that is objective and free from commercial bias. All instructors are required to disclose any relevant financial relationships related to the context of their participation. Their disclosure statements will be available for inspection. Each faculty member also will disclose discussions of unlabeled or investigative use of any commercial product..


Back to top


Speakers and Program Committee

Speakers
Nicholas Hastie, CBE, FRS, FRSE
Director, MRC Human Genetics Unit and Director
Institute of Genetics and Molecular Medicine, University of Edinburgh
Wt1 and mesenchyme regulation in Wilms tumor, development and tissue homeostasis

Jeffrey Toretsky, MD
Georgetown Lombardi Cancer Center
Targeting chromosomal translocation fusion proteins with small molecules

Michael Atkins, MD
Deputy Director
Georgetown Lombardi Cancer Center
Current and future treatment options for adult RCC: Lessons Learned

D. Ashley Hill, MD
Chief, Division of Pathology, Children’s National Medical Center
DICER1 mutations and risk for tumors of the kidney

Malcolm Smith, MD, PhD
Associate Branch Chief
Pediatric Oncology, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI)
Preclinical testing for renal tumors – Lessons from the Pediatric Preclinical Testing Program (PPTP)

Marston Linehan, MD
Chief of the Urologic Oncology Branch, National Cancer Institute
The genetic basis of kidney cancer: A metabolic disease



Program Committee
  • Jeffrey Dome, MD, PhD, Children’s National Medical Center, Washington DC, USA
  • James Geller, MD, Cincinnati Children’s Medical Center, Cincinnati, USA
  • Norbert Graf, MD, University Hospital Homburg, Homburg, Germany
  • Vicki Huff, PhD, MD, Anderson Cancer Center, Houston, USA
  • Kathy Pritchard-Jones, MBBS, University College London Institute for Child Heath, London, UK

Back to top

Poster Presentations

Authors to be available at posters on May 9 and May 10 for the morning coffee breaks
Cajaiba MM et al.: Revisiting the morphological spectrum of pediatric cystic nephromas: the COG experience
Doros, L et al.: Somatic DICER1 mutations in sporadic cases of cystic nephroma
Wu MK et al.: Biallelic DICER1 mutations occur in Wilms tumors
Vokuhl, C: 1q gain in Wilms tumors treated in the SIOP2001/GPOH trial
Pritchard-Jones K et al.: Copy number analysis of 1q gain in Wilms tumor by multiplex ligation-dependent probe amplification
Dainese L et al.: 1p and 16q allelic loss in Wilms tumors (Nephroblastoma) in the SFCE/SIOP 2001 Nephroblastoma trial – Are they correlated with pathology
Romao et al.: Can preoperative identification of constitutional molecular signatures for multifocality impact surgical treatment for Wilms tumor?
Venkatramani et al.: Treatment of multiply relapsed Wilms Tumor with vincristine, irinotecan, temozolomide, and bevacizumab

Back to top


Back to top
 


 
Quick Links
Visiting and Staying at Children's
Refer a Patient to Children's
Find A Doctor at Children's
Request an Appointment at Children's
Online Bill Pay
Give to Children's
Get Involved at Children's
Subscribe to Children's RSS Feed